• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Oncaspar (pegaspargase)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

April 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.6 Hepatotoxicity and Abnormal Liver Function
  • Hepatotoxicity and abnormal liver function, including elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin (direct and indirect), and depression of serum albumin, and plasma fibrinogen can occur. Perform appropriate monitoring.

6 ADVERSE REACTIONS

  • added .... hepatotoxicity and hyperlipidemia